Every 8-K that SkinHealth Systems Inc. (SKIN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SKIN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKIN filings page.
SkinHealth Systems Inc. (SKIN) announced that its Board of Directors has promoted Chief Financial Officer Michael Monahan to the role of Chief Financial and Operating Officer, effective September 3, 2026. In this expanded role, he now oversees all financial operations as well as the company’s supply chain, manufacturing, logistics, and customer experience functions.
In connection with the promotion, Mr. Monahan’s annual base salary will increase from $515,000 to $555,000, effective September 15, 2026. The company states there are no special arrangements or understandings leading to his appointment, no family relationships with directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
SkinHealth Systems Inc. reported that Sheri Lewis has decided to resign from her role as Chief Operations, Quality and Technology Officer to pursue other business opportunities outside the company. She notified the company on August 10, 2026, and will step down effective August 28, 2026.
The company states that Ms. Lewis’ resignation is not due to any disagreement with SkinHealth Systems, its board of directors, or management regarding operations, policies, or practices.
SkinHealth Systems Inc. reported second quarter 2026 results with net sales of $72.1 million, a decrease of 7.8% from Q2 2025, as both delivery systems and consumables sales declined. The company sold 770 delivery systems, down from 957, while its active installed base grew to 36,516 systems.
Profitability metrics improved. Gross margin rose to 68.4% (adjusted 71.8%) from 62.8%, and operating expenses fell to $45.8 million from $51.8 million, reflecting lower personnel-related costs. SkinHealth posted a net loss of $2.7 million versus prior-year net income of $19.7 million, largely because Q2 2025 included an $18.1 million gain related to exchanges and repurchases of its 2026 notes. Adjusted EBITDA increased to $17.0 million, up from $13.9 million, with margin improving to 23.6%.
For the third quarter of 2026, management projects net sales of $65–$70 million and adjusted EBITDA of $5–$7 million. Full-year 2026 guidance calls for net sales of $280–$290 million and adjusted EBITDA of $39–$46 million. Cash, cash equivalents, and restricted cash totaled $206.1 million at June 30, 2026.
SkinHealth Systems Inc. has agreed to a proposed settlement of a federal securities class action for a total cash payment of $18,000,000, subject to court approval. The company will fund $3,000,000 from its own cash, while insurers are expected to contribute $15,000,000. The settlement is intended to resolve claims by investors who traded the company’s Class A common stock and related options between May 10, 2022 and November 13, 2023. Plaintiffs’ attorneys plan to seek fees and costs estimated not to exceed 30% of the cash payment, or $5,400,000, with the net amount to be distributed to eligible class members after expenses and awards, if the court approves the agreement.
SkinHealth Systems Inc. reported results of its annual stockholder meeting held virtually on June 10, 2026. A quorum was achieved, with 93,406,914 of 129,584,184 Class A shares entitled to vote as of the April 16, 2026 record date, representing approximately 72.08% participation.
Stockholders elected nine directors to one-year terms, including Brenton L. Saunders and eight other nominees, with each receiving more votes for than withheld. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In an advisory, non-binding vote on executive pay, stockholders approved the compensation of the company’s named executive officers as described in the proxy statement, with 58,604,735 votes for, 12,346,541 against, 1,021,201 abstentions, and 21,434,437 broker non-votes.
SkinHealth Systems Inc. amended an earlier report to add details of the severance package for former Chief Revenue Officer Ronald Menezes, whose employment was terminated without cause effective May 6, 2026. The company states his departure did not involve any disagreement over financial reporting, operations, policies, or practices.
Under a Severance and General Release Agreement dated May 15, 2026, Mr. Menezes will receive total cash severance of $463,000, paid over 12 months, plus a pro-rata 2026 annual bonus payable in March 2027. He may continue health, dental, and vision coverage under COBRA with the employer portion of premiums reimbursed while severance is paid. In exchange, he provides a broad release of claims and agrees to confidentiality, non-disparagement, protection of proprietary information, return of company property, and a one-year covenant not to solicit company employees to join a competitor.
SkinHealth Systems Inc. received a notice from Nasdaq that its Class A common stock no longer meets the exchange’s $1.00 minimum bid price requirement, after trading below $1.00 for 30 consecutive business days from March 26, 2026 through May 7, 2026. The stock remains listed on the Nasdaq Capital Market under the symbol SKIN, and trading is not immediately affected.
The company has 180 calendar days, until November 4, 2026, to regain compliance by having a closing bid of at least $1.00 per share for a minimum of ten consecutive business days, which Nasdaq may extend up to twenty days. If it fails to comply, SkinHealth may qualify for an additional 180-day period, potentially including a reverse stock split. If compliance is still not achieved, the stock could be delisted, although the company would have the right to appeal.
SkinHealth Systems Inc. reported mixed first quarter 2026 results with a lower full-year outlook. Net sales were $64.9 million, down (6.7)% from Q1 2025, as both delivery systems and consumables declined. Gross margin was 68.5% versus 69.8%, while adjusted gross margin held at 72.2%.
Operating expenses fell sharply to $46.2 million from $60.6 million, helping narrow net loss to $(6.6) million from $(10.1) million. Adjusted EBITDA improved to $8.5 million from $7.3 million, and the active install base grew to 36,419 systems.
The company cut its 2026 outlook, now guiding net sales of $280–$295 million and adjusted EBITDA of $35–$45 million, citing continued pressure on device sales and challenging market conditions. Cash, cash equivalents, and restricted cash were $204.4 million at March 31, 2026, down from $232.7 million at year-end 2025.
SkinHealth Systems Inc. reported that its Board of Directors terminated the employment of Chief Revenue Officer Ronald Menezes without cause, effective May 5, 2026. The company stated that his departure did not arise from any disagreement over financial reporting, operations, policies, or practices.
SkinHealth plans to negotiate a separation agreement with Menezes setting out any payments or benefits related to his termination. No material terms have been determined yet, and the company expects to file an amendment within four business days after a definitive separation agreement is executed.
SkinHealth Systems Inc., formerly The Beauty Health Company, has changed its corporate name and updated its charter and bylaws to reflect a strategic focus on clinically driven, science‑backed medical aesthetics. The company will continue trading on the Nasdaq Capital Market under the ticker “SKIN.”
The Board appointed three new independent directors effective April 17, 2026: operations executive Kenneth Tripp, aesthetic medicine expert Dr. Sachin Shridharani, and global beauty and consumer brands leader E. Scott Beattie. The Board temporarily expands to 11 members and is expected to return to 9 following the 2026 annual meeting when two current directors depart.
The company highlights Hydrafacial as its flagship brand and notes an installed base of more than 36,000 devices worldwide, supported by a device‑plus‑consumables model and commercial infrastructure across North America, Europe, and Asia‑Pacific.
The Beauty Health Company reported mixed 2025 results, with lower sales but much stronger profitability. Net sales were $300.8M, down 10.0% from 2024, as delivery system sales fell even though consumables held up.
Gross margin improved sharply to 65.3% from 54.5%, helped by fewer inventory charges and a richer mix of consumables. Net loss narrowed to $9.5M from $29.1M, and adjusted EBITDA increased to $45.1M from $12.3M, reflecting lower operating expenses and better margins. Cash, cash equivalents, and restricted cash were $232.7M at December 31, 2025, while convertible senior notes declined to $364.4M in total. For 2026, the company guides net sales of $285–$305M and adjusted EBITDA of $35–$45M, implying relatively stable revenue with continued focus on profitability.
The Beauty Health Company filed an 8-K to notify stockholders about a proposed settlement of a consolidated stockholder derivative action in Delaware Chancery Court. The settlement is a non-monetary resolution focused on corporate governance reforms and does not include any cash distribution to stockholders.
The company agreed to measures such as a Quality Ombudsman role, enhanced inventory and returns monitoring, stronger oversight of public financial projections, an expanded clawback policy, and formalized disclosure and product committees. Plaintiffs’ counsel negotiated a proposed fee and expense award of $737,500, to be paid by Beauty Health and/or its insurers, subject to court approval at a settlement hearing on May 13, 2026.
The Beauty Health Company (SKIN) furnished an update on its fiscal quarter ended September 30, 2025. The company issued a press release and will hold a conference call covering its results, with the release provided as Exhibit 99.1.
The materials include non-GAAP financial information, with GAAP-to-non-GAAP reconciliations in Exhibit 99.1. The Item 2.02 information is furnished, not filed. The company also notes it shares material information via SEC filings, press releases, public calls, and its investor relations website.
The Beauty Health Company (SKIN) appointed Dr. Philippe Schaison to its Board, effective October 30, 2025. The Board and its Nominating and Corporate Governance Committee determined he is an independent director under Nasdaq and SEC rules. He was also appointed to the Nominating and Corporate Governance Committee and the Compensation Committee.
Director compensation will follow the company’s standard non‑employee director program and be prorated from his start date. The company furnished a press release on November 3, 2025, announcing the appointment.
The Beauty Health Company filed an amended report detailing the separation terms for former Chief Executive Officer Marla Beck, whose employment ended without cause effective September 30, 2025. She will serve in an advisory capacity from October 1 through no later than December 31, 2025, receiving her current compensation during this period, stated as $250,000 payable bi‑weekly.
Under the separation agreement, Ms. Beck will receive continued payment of Base Salary for eighteen months, a prorated bonus for the year of termination and any earned but unpaid prior‑year bonus, reimbursement of the employer portion of COBRA premiums for up to eighteen months, and up to $10,000 in legal fees. Her performance share units with a grant‑date value of $1,700,000 vest in full as of the Separation Date. The company states the departure did not arise from any disagreement related to financial reporting, operations, policies, or practices.
The Beauty Health Company appointed Hatem Malha as President, CEO and director and disclosed the material terms of his employment agreement. His base salary will be $800,000 per year (pro-rated if partial year). He will receive a $450,000 one-time cash bonus payable within 14 days of the effective date that is repayable if he resigns without specified cause or is fired for cause within 12 months. He is eligible for an annual performance bonus targeted at 125% of base salary and two one-time equity awards: an Initial equity grant of $2,556,000 split 75% in RSUs and 25% in PSUs, and a 2025 equity grant of $2,000,000 split 75% RSUs and 25% PSUs, each subject to board approval and the company's Incentive Plan vesting terms.
The Beauty Health Company (SKIN) filed a Current Report on Form 8-K reporting a material event dated September 4, 2025. The filing incorporates by reference a Supplemental Indenture No. 1 dated September 4, 2025 among The Beauty Health Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, acting as trustee and collateral agent. The document includes an exhibit list and an embedded Inline XBRL cover page data file. The report is signed by Michael Monahan, Chief Financial Officer.